Filing Flows › Arcturus Therapeutics Holdings (ARCT) › Q3 2026 › vs Q3 2025
Arcturus Therapeutics Holdings (ARCT) Q3 2026 vs Q3 2025 (year over year)
Arcturus Therapeutics Holdings's revenue rose $1.1M (+7%) from $17.2M in Q3 2025 to $18.3M in Q3 2026. The biggest changes: Collaboration Revenue +$2.7M (+19%); Grant −$1.6M (-52%).
Arcturus Therapeutics Holdings, Q3 2026: revenue $18.3M (+7% year over year), operating margin -50.2%, net loss $7.4M, operating cash flow −$6.9M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Collaboration Revenue | $16.9M | $14.2M | $2.7M | +19% |
| Grant | $1.4M | $3.0M | −$1.6M | -52% |
| Revenue | $18.3M | $17.2M | $1.1M | +7% |
| Other income, net | $1.8M | $3.1M | −$1.3M | -42% |
| Net loss | $7.4M | $13.4M | −$6.0M | -45% |
| Costs & expenses | $27.5M | $33.7M | −$6.2M | -18% |
| Operating costs | $27.5M | $33.7M | −$6.2M | -18% |
| Research & development | $17.0M | $23.3M | −$6.3M | -27% |
| General & admin | $10.5M | $10.4M | $86K | +0.8% |
| Operating cash sources | $11.5M | $23.7M | −$12.1M | -51% |
| Depreciation & amortization | $600K | $800K | −$200K | -25% |
| Share-based compensation | $4.0M | $5.7M | −$1.7M | -29% |
| Cash used in operations | $6.9M | $17.2M | −$10.2M | -60% |
| Net loss absorbed | $7.4M | $13.4M | −$6.0M | -45% |
| Working capital & other | $4.1M | $10.2M | −$6.1M | -60% |
Questions
How much did Arcturus Therapeutics Holdings's revenue grow year over year in Q3 2026?
Arcturus Therapeutics Holdings's revenue rose $1.1M (+7%) from $17.2M in Q3 2025 to $18.3M in Q3 2026.
What drove Arcturus Therapeutics Holdings's revenue change in Q3 2026?
Collaboration Revenue +$2.7M (+19%); Grant −$1.6M (-52%).